Key Insights• According to the research report, "Argentina EPA & DHA Market Outlook, 2031," published by Actual Market Research, the Argentina EPA & DHA Market is anticipated to grow at more than 7.43% CAGR from 2026 to 2031.The Argentine EPA & DHA market is gradually expanding as the country faces a high burden of cardiovascular and noncommunicable disease driven by population aging, dietary patterns high in red meat and low in oily fish, and growing consumer interest in preventive nutrition. Argentina's population is estimated at approximately 47 million, and the country is among the most demographically aged in Latin America. According to Ministry of Health data for 2024, Argentina recorded 376,405 deaths, of which noncommunicable diseases accounted for 69.1%, with cardiovascular disease representing 40.4% of noncommunicable disease deaths, making it the leading cause of death in the country. Heart failure, ischemic heart disease, and cerebrovascular disease were the principal cardiovascular causes. The growing clinical burden is placing additional pressure on Argentina's public, social security (obras sociales), and private prepaid health systems, as well as the consumer health sector, to strengthen access to EPA and DHA through dietary supplements, medicines, fortified foods, and infant nutrition.• Argentina's EPA & DHA market is characterized by a mixed ecosystem comprising domestic pharmaceutical laboratories, multinational nutrition companies, pharmacy chains, health food retailers, and an established pet food industry. Domestic laboratories play a central role in the supply of prescription and over-the-counter omega-3 products, while pharmacy chains such as Farmacity and independent pharmacies function as the primary distribution channels for omega-3 supplements, complemented by e-commerce platforms such as Mercado Libre.

Infant formula is supplied by multinational companies including Nestlé, Danone (Nutricia Bagó), and Reckitt (Mead Johnson). Argentina's macroeconomic stabilization and import liberalization since 2024 have improved the availability of imported refined fish oil, krill oil, and finished omega-3 products, while reducing barriers for international brands entering the market.• Regulatory oversight for EPA and DHA products is administered by the National Administration of Drugs, Food and Medical Technology (ANMAT) through the National Food Institute (INAL) under the Argentine Food Code (Código Alimentario Argentino, CAA). Omega-3 dietary supplements are regulated as suplementos dietarios under the CAA, requiring product and establishment registration (RNPA and RNE), while prescription omega-3 products are regulated as medicines. In January 2025, the government published Decree 35/2025, amending the regulation of the Argentine Food Code to allow foods authorized by health authorities in countries with high sanitary surveillance or reciprocity agreements to be imported on the basis of a free-sale certificate and a sworn import declaration. The Argentine EPA & DHA market is largely supplied through imported refined oils, with local laboratories handling encapsulation, packaging, and distribution.Market Outlook• A defining characteristic of Argentina's EPA & DHA market is the progressive opening of the regulatory and trade environment. Decree 35/2025, published in January 2025, simplified import procedures for ANMAT-regulated foods, enabling faster entry of internationally approved omega-3 supplements, fortified foods, and ingredients.

In December 2024, ANMAT Dispositions 11378/2024 and 11362/2024 amended the implementation manual for the front-of-pack labelling law, stipulating that only nutrients from ingredients added during production count toward warning seals, a change that affects how omega-3-enriched products and naturally fat-rich foods such as nuts and fish are labelled. In May 2026, the government announced plans for a bill to repeal the black octagon warning system altogether as part of its broader deregulation agenda. These changes are expected to reduce compliance costs and broaden product availability, while encouraging competition between domestic laboratories and imported brands.• The market also reflects Argentina's growing emphasis on cardiovascular prevention and healthy aging. Professional bodies such as the Argentine Society of Cardiology and the Argentine Federation of Cardiology continue to promote awareness of cardiovascular risk factors, including dyslipidemia and hypertension, supporting physician recommendation of omega-3 supplementation for selected patients. In infant nutrition, Argentina recorded 413,135 live births in 2024, compared with 770,040 in 2015, according to Ministry of Health vital statistics, while UNFPA Argentina estimates the total fertility rate at 1.2 children per woman. The steep decline in births is constraining infant formula volumes but encouraging manufacturers to compete on premium DHA- and ARA-fortified formulations.Market DynamicsDriver: High cardiovascular disease burden and demographic aging supported by physician and pharmacist recommendationArgentina's EPA & DHA market is primarily driven by the high prevalence of cardiovascular and metabolic conditions associated with demographic aging and dietary patterns.

Cardiovascular disease accounted for 40.4% of noncommunicable disease deaths in 2024, equivalent to approximately 28% of all deaths, according to Ministry of Health data. Heart failure was the leading cardiovascular cause of death at 25.1%, followed by ischemic heart disease at 21.7% and cerebrovascular disease at 16.9%. Consumption of oily fish remains low relative to meat intake, creating a structural gap in dietary EPA and DHA. Argentina's aging population is reinforcing demand for products that support cardiovascular, cognitive, and joint health, while physicians and pharmacists frequently recommend omega-3 supplements for triglyceride management and general wellness. As awareness of cardiovascular prevention continues to grow, pharmacies are witnessing steady demand for EPA and DHA products from established domestic laboratories and international brands.Challenge: Macroeconomic volatility, purchasing power constraints, and dependence on imported oilsOne of the principal challenges facing Argentina's EPA & DHA market is the country's history of macroeconomic volatility and its dependence on imported refined marine oils. Although inflation has declined significantly since 2024, consumer purchasing power remains constrained for many households, limiting spending on premium supplements.

Most refined fish oil, krill oil, and algal oil used in Argentine products is imported, exposing manufacturers to exchange rate movements and global raw material prices. Peru's first 2026 north-central anchovy quota was set at 1,914,049 tonnes, approximately 36% lower than in 2025, following a coastal El Niño event, while the Antarctic krill fishery closed early in both 2025 and 2026. Additionally, the rapid decline in births, from 770,040 in 2015 to 413,135 in 2024, is reducing the addressable market for infant formula. Together, these factors contribute to price sensitivity and slower adoption of premium high-concentration and algal omega-3 formats.Trend: Import liberalization, e-commerce growth, and expansion of premium formatsArgentina is experiencing a gradual shift toward a more open and competitive omega-3 market supported by deregulation and digital retail. Decree 35/2025 enables faster import of internationally approved supplements, while the relaxation of import restrictions since 2024 has improved the availability of krill oil, algal DHA, and high-concentration fish oils. E-commerce platforms such as Mercado Libre are expanding consumer access to international brands and specialty formats, while pharmacy chains are developing private-label omega-3 ranges.

Simultaneously, the pet nutrition sector is growing as pet humanization increases and premium pet foods incorporating fish oil gain share. The growing emphasis on sports nutrition, healthy aging, and cognitive health is also boosting demand for EPA- and DHA-rich products, while the potential repeal of front-of-pack warning seals could reshape the positioning of omega-3-fortified foods.Policies• Argentine Food Code and Dietary Supplement Registration: Omega-3 dietary supplements containing EPA and DHA are regulated as suplementos dietarios under the Código Alimentario Argentino. Products must be registered in the National Registry of Food Products (RNPA), and manufacturing or importing establishments must be registered in the National Registry of Establishments (RNE), with labelling required to comply with CAA provisions and prohibitions on therapeutic claims.• Decree 35/2025 Import Simplification: Published in January 2025, Decree 35/2025 amended Decree 2126/1971, which regulates the Argentine Food Code, allowing foods authorized in countries with high sanitary surveillance or reciprocity agreements to be imported based on a free-sale certificate and a sworn import declaration, and allowing exports to comply solely with destination country requirements.• Front-of-Pack Labelling Law: Packaged foods are subject to the front-of-pack labelling law, implemented through Decree 151/22, requiring black octagon warning seals for excess sugars, sodium, saturated fats, total fats, and calories. ANMAT Dispositions 11378/2024 and 11362/2024, published in December 2024, limited the calculation of warning seals to nutrients from added ingredients, and in May 2026 the government announced plans to seek repeal of the warning system.• Medicine Registration: Prescription and over-the-counter omega-3 medicines must be registered with ANMAT under Law 16.463 and its regulations, including evidence of quality, safety, efficacy, and good manufacturing practices.• Infant Formula and Breast-milk Substitute Marketing: Infant formulas are regulated under specific provisions of the Argentine Food Code, with DHA and ARA permitted as optional ingredients within defined limits, while marketing practices are guided by the principles of the International Code of Marketing of Breast-milk Substitutes.Segment AnalysisArgentina EPA & DHA Market By Product Type• Docosahexaenoic Acid (DHA) maintains an important position within Argentina, particularly in infant formula, prenatal supplements, and children's nutrition products, with DHA widely included in formulas marketed by multinational manufacturers.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in Argentina, driven by increasing physician recommendation of high-EPA concentrates and omega-3 medicines for triglyceride management and cardiovascular risk reduction.Argentina EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in Argentina due to its cost-effectiveness and broad consumer familiarity. Refined fish oil is largely imported from Peru and Chile, while domestic fisheries for hake and Argentine anchovy supply limited quantities of fish oil, mainly for feed applications.• Algae Oil maintains a growing position within Argentina, particularly in infant formula and vegan supplements, supplied by multinational algal oil producers.• Krill Oil is a premium source category available through pharmacies, health food stores, and e-commerce, benefiting from improved import access since 2024.• Other Marine Sources hold a niche position in the Argentine market, including cod liver oil and salmon oil, primarily used in traditional supplements and pet nutrition.Argentina EPA & DHA Market By Application• Dietary Supplements represent the largest application segment in Argentina, distributed through pharmacies, health food stores, and e-commerce, with omega-3 among the most recommended supplements for cardiovascular and cognitive health.• Pharmaceuticals represent an important application segment, with omega-3 medicines produced and marketed by domestic laboratories for hypertriglyceridemia and cardiovascular risk management, reimbursed in part through obras sociales and prepaid health plans.• Infant Formula represents a strategically important application segment, with DHA included in most formulas. Births fell to 413,135 in 2024, reducing volumes but supporting premiumization.• Food & Beverages encompasses omega-3-enriched milk, eggs, and functional foods, whose labelling has been affected by the December 2024 changes to warning seal calculations.• Clinical Nutrition & Medical Foods includes enteral and parenteral nutrition products containing fish oil, used in public and private hospitals for critically ill and surgical patients.• Pet Nutrition represents the fastest-growing application segment in Argentina, supported by rising pet humanization and the expansion of premium pet foods and supplements incorporating fish oil.Major EPA & DHA Manufacturers Operating in Argentina• Nestlé, Danone (Nutricia Bagó), Reckitt (Mead Johnson), Abbott, Laboratorios Bagó, Roemmers, Elea, Raffo, dsm-firmenich, KD Pharma Group, and Aker BioMarine are leading players in the Argentine EPA & DHA market, offering finished supplements, omega-3 medicines, DHA-fortified infant formula, and refined fish oil, algal oil, and krill oil ingredients.

Their strong presence, established pharmacy distribution, medical promotion networks, and relationships with healthcare professionals have driven adoption across the Argentine market.• The market is also supported by contract manufacturers, ingredient importers, and pet food producers that provide formulation, encapsulation, and distribution support. With improving macroeconomic conditions and import liberalization, Argentina is positioned to see broader availability of international omega-3 products.Argentina EPA & DHA Supply and Pricing Economics• EPA and DHA products in Argentina represent value-added nutritional products whose pricing depends on source, concentration, brand positioning, and import costs. Pricing varies considerably between standard fish oil, high-concentration oils, krill oil, and algal oil.• Retail pricing is highly sensitive to the exchange rate and inflation, although the decline in inflation since 2024 has improved price stability. Refined fish oil prices normalized by late 2024 after the El Niño-related disruption, but the reduced 2026 Peruvian quota is expected to place renewed pressure on raw material costs.• Supplements are largely paid out-of-pocket, while omega-3 medicines may be partially covered by obras sociales and prepaid health plans for eligible patients.• Import simplification under Decree 35/2025 is expected to increase competition and gradually reduce prices for imported omega-3 products.Market Outlook by Consumer Health Spending and Supply Infrastructure• Argentina's EPA & DHA market growth is strongly linked to macroeconomic stabilization, consumer purchasing power, and the expansion of pharmacy and e-commerce channels, although price sensitivity and import dependence remain significant factors influencing adoption.• Private consumer spending drives the supplement segment, while obras sociales and prepaid health plans influence access to omega-3 medicines. Domestic laboratories maintain strong positions through medical promotion and pharmacy relationships.• The future growth opportunity for EPA and DHA in Argentina depends on sustained economic stability, continued import liberalization, consumer education on omega-3 benefits, and expansion of the pet nutrition and healthy aging segments. Greater integration of e-commerce, premium krill and algal formats, and physician-led cardiovascular prevention will likely become key strategies for long-term market development.Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.